CYP2D610等位基因与口服他莫昔芬的乳腺癌患者发生潮热的相关性

Association between CYP2D610 Allele and Hot Flashes in Breast Cancer Patients Treated with Oral Tamoxifen

目的分析CYP2D6*10等位基因与口服他莫昔芬的乳腺癌患者发生潮热的相关性。方法选取2017年1月-2018年10月我院采用他莫昔芬口服治疗的0-Ⅲ期乳腺癌患者50例,根据是否发生潮热分为发生组和未发生组。采用PCR直接测序法检测患者CYP2D6*10等位基因rs1065852[A/G]位点基因类型,分析CYP2D6*10等位基因类型在两组患者中的分布差异和患者发生潮热的影响因素。结果入组患者rs1065852[A/G]位点检测到野生型纯合子14例(28%)、杂合子13例(26%)、突变型纯合子23例(46%),携带不同rs1065852[A/G]基因型患者的潮热发生率比较,差异无统计学意义(χ~2=2.176,P=0.337)。结论 CYP2D6*10等位基因rs1065852[A/G]位点多态性与口服他莫昔芬乳腺癌患者发生潮热的频率无明显相关性,但该研究结果还需更大样本量进行证实。

Objective To analyze the association between CYP2D6*10 allele and hot flashes in breast cancer patients treated with tamoxifen (TAM).Methods Fifty patients with stage 0-Ⅲ breast cancer who took TAM orally in our hospital between January 2017 and October 2018 were divided into the hot-flash group and the non-hot-flash group according to the occurrence of hot flashes.The genotype of CYP2D6*10 allele rs1065852 [A/G] was detected by PCR direct sequencing.The distribution differences of CYP2D6*10 allele in each group and the influencing factors of hot flashes were analyzed by Chi square test.Test level α=0.05.Results Among 50 breast cancer patients with TAM,there were 14 cases (28%) of homozygous wild type,13 cases (26%) heterozygote and 23 cases (46%) of mutant homozygotes at rs1065852 [A/G] locus.There was no statistic significant difference in the incidence of hot flashes between patients with different rs1065852 [A/G] genotypes (χ~2=2.176,P=0.337).Conclusion The results suggested that the polymorphism of the CYP2D6*10 allele rs1065852 [A/G] had no correlation with the frequency of hot flashes in breast cancer patients treated with oral tamoxifen.Yet the results need confirmation by larger sample study.